In our prospective cohort study, we found that four serum biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C) were significantly associated with a higher risk of the CO among patients with CCM. The gene discussed is NPPB; the disease is cerebral cavernous malformation.